Clinical Trials on Neisseria Meningitides Meningitis

Total 456 results

ANRS, Emerging Infectious Diseases
St George's, University of London; Yaounde Central Hospital

Unknown

Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS (PreCASA)

Cryptococcal Meningitis

Cameroon
University of Pharmacy, Yangon

Completed

Clinical Effectiveness and Safety of Amphotericin B With Flucytosine-Fluconazole Therapy for Cryptococcal Meningitis

Cryptococcal Meningitis

Myanmar
University of Zimbabwe
Centers for Disease Control and Prevention

Completed

CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa (CryptoART)

Cryptococcal Meningitis

Zimbabwe
National Hospital for Tropical Diseases, Hanoi,...

Completed

Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report

Cryptococcal Meningitis

Vietnam
National Institute of Allergy and Infectious Diseases...

Completed

Amphotericin Alone or in Combination With Fluconazole for AIDS-Associated Meningitis

Cryptococcal Meningitis

United States, Thailand
Zekai Tahir Burak Women's Health Research and Education...

Unknown

Epidemiology, Treatment and Prognosis of Neonatal Meningitis in Turkey: A Multicenter Study (NEO-MENINGITIS)

Neonatal Meningitis

Turkey
Peking Union Medical College Hospital
CSPC Ouyi Pharmaceutical Group Co., Ltd.

Not yet recruiting

Clinical Study of ABCD in the Treatment of Cryptococcal Meningitis

Cryptococcal Meningitis

China
Shanghai Children's Medical Center
BioMérieux

Unknown

Clinical Evaluation of the FilmArray® Meningitis/Encephalitis (ME) Panel

Meningitis/Encephalitis
Chiron Corporation

Unknown

Kinetic of Immune Memory Response After Re-Vaccination With Meningococcal Vaccine

Meningococcal Disease; Meningococcal Meningitis

United Kingdom
Huashan Hospital

Enrolling by invitation

Amphotericin B for Non-HIV Cryptococcal Meningitis Patients (ABNCM)

Antifungal Agents | Cryptococcal Meningitis

China
University of Zimbabwe
AIDS Care Research in Africa

Completed

Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa

HIV Infections | Cryptococcal Meningitis

Zimbabwe
Botswana-UPenn Partnership
University of Pennsylvania; Doris Duke Charitable Foundation

Completed

Optimal Time to Start Antiretroviral Therapy in HIV-infected Adults With Cryptococcal Meningitis (Crypto)

HIV Infections | Cryptococcal Meningitis

Botswana
Oxford University Clinical Research Unit, Vietnam
University of Rochester; University of Liverpool; Liverpool School of Tropical... and other collaborators

Completed

Treatment With Tamoxifen in Cryptococcal Meningitis

Hiv | Meningitis | Meningoencephalitis | Meningitis Streptococcal

Vietnam
National Institute of Allergy and Infectious Diseases...

Completed

High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals

HIV Infections | Cryptococcal Meningitis

Kenya, Thailand, Uganda, United States, Peru, South Africa, Zimbabwe, India
First Affiliated Hospital of Zhejiang University
Wenzhou Central Hospital

Unknown

Three Induction Treatments on Cryptococcal Meningitis (TITOC)

HIV/AIDS | Cryptococcal Meningitis

China
Beijing Children's Hospital
First Affiliated Hospital of Xinjiang Medical University; Xingtai People's... and other collaborators

Unknown

Application of Next Generation Sequencing Technique in Pediatric Bacterial Meningitis

Next Generation Sequencing | Pediatric Bacterial Meningitis

China
ANRS, Emerging Infectious Diseases
Institut Pasteur; Hôpital Necker-Enfants Malades; Hospital Avicenne; CHU Kamenge... and other collaborators

Unknown

Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa (Flucocrypto)

HIV | Cryptococcal Meningitis

Burundi, Côte D'Ivoire
London School of Hygiene and Tropical Medicine
University of Zimbabwe; Botswana Harvard AIDS Institute Partnership; Infectious...

Completed

The Lived Experience of Participants in an African Randomised Trial (LEOPARD)

HIV | Cryptococcal Meningitis

Zimbabwe, Botswana, Uganda
University of Minnesota
Centers for Disease Control and Prevention; Makerere University; Infectious Diseases...

Completed

Operational Research for Cryptococcal Antigen Screening (ORCAS)

Cryptococcosis | Cryptococcal Meningitis | Cryptococcus Neoformans

Uganda
Sanofi Pasteur, a Sanofi Company

Completed

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers

Meningococcal Meningitis

Germany
Sanofi

Completed

Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
University of Minnesota
National Institute of Allergy and Infectious Diseases (NIAID); Makerere University and other collaborators

Completed

Cryptococcal Optimal ART Timing Trial (COAT)

HIV Infections | AIDS | Cryptococcal Meningitis

Uganda, South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland, Germany, Hungary, Spain
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Finland
Sanofi Pasteur, a Sanofi Company

Completed

Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Public Health England

Completed

Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)

Meningococcal Meningitis

United Kingdom
JN-International Medical Corporation

Completed

Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study

Meningococcal Infections | Meningococcal Meningitis

United States
Novartis Vaccines

Completed

Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

Meningococcal Infections | Meningococcal Meningitis

Argentina, Chile, Czech Republic, Hungary, Italy
Armauer Hansen Research Institute, Ethiopia
World Health Organization; Addis Ababa University; LSHTM,UK

Completed

Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine (ETH-TVT)

Meningococcal Meningitis

Ethiopia
CanSino Biologics Inc.

Not yet recruiting

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Epidemic Meningitis
Aimei Vacin BioPharm (Zhejiang) Co., Ltd.

Not yet recruiting

A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine

Meningococcal Meningitis

China
CanSino Biologics Inc.

Not yet recruiting

A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds

Meningococcal Meningitis
Centre Hospitalier Universitaire Dijon

Recruiting

Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis (AddaMAP)

Pneumococcal Meningitis

France
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
Kamuzu University of Health Sciences

Completed

Infant Severe Sepsis and Bacterial Meningitis in Malawi (Infaseme)

Infant Bacterial Meningitis

Malawi
Novartis

Completed

Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.

Meningitis, Meningococcal, Serogroup B

Poland
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos

Meningitis, Meningococcal, Serogroup C

Brazil
Novartis Vaccines

Completed

Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1

Meningococcal Disease | Meningococcal Meningitis

Spain, Italy, United Kingdom, Czech Republic
Novartis Vaccines

Completed

Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines

Meningococcal Disease | Meningococcal Meningitis

Chile, Colombia, Panama
Novartis Vaccines

Completed

A Multi-center, Observer-blind, Placebo-controlled, Randomized Study to Evaluate the Immunogenicity and Safety of MenACWY in Adolescents and Adults in Korea

Meningococcal Disease | Meningococcal Meningitis

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico

Clinical Trials on Neisseria Meningitides Meningitis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations